Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.

[1]  H. K. Jeon,et al.  TERT promotes cellular and organismal survival independently of telomerase activity , 2008, Oncogene.

[2]  M. Akiyama,et al.  Leukemic cells with increased telomerase activity exhibit resistance to imatinib , 2008, Leukemia & lymphoma.

[3]  O. Yamada,et al.  STAT3 and PKC Differentially Regulate Telomerase Activity During Megakaryocytic Differentiation of K562 Cells , 2007, Cell cycle.

[4]  Hisashi Yamada,et al.  Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile. , 2006, Leukemia research.

[5]  D. Alexander,et al.  Fusion tyrosine kinase mediated signalling pathways in the transformation of haematopoietic cells , 2006, Leukemia.

[6]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[7]  D. Levy,et al.  Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target , 2005, Nature Medicine.

[8]  O. Yamada,et al.  IL-2 Increases Human Telomerase Reverse Transcriptase Activity Transcriptionally and Posttranslationally through Phosphatidylinositol 3′-Kinase/Akt, Heat Shock Protein 90, and Mammalian Target of Rapamycin in Transformed NK Cells , 2005, The Journal of Immunology.

[9]  O. Yamada,et al.  Transient posttranslational up-regulation of telomerase activity during megakaryocytic differentiation of K562 cells. , 2004, Biochemical and biophysical research communications.

[10]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[11]  D. Corey,et al.  Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. , 2003, Cancer research.

[12]  Hisashi Yamada,et al.  Overexpression of Telomerase Confers a Survival Advantage through Suppression of TRF1 Gene Expression While Maintaining Differentiation Characteristics in K562 Cells , 2003, Cell transplantation.

[13]  Matthew B. Wilson,et al.  Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr–Abl signal transduction and oncogenesis , 2002, Oncogene.

[14]  Matthew B. Wilson,et al.  The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells , 2002, The EMBO journal.

[15]  Robert A. Weinberg,et al.  Telomerase contributes to tumorigenesis by a telomere length-independent mechanism , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Fishel,et al.  Fusion Tyrosine Kinases Induce Drug Resistance by Stimulation of Homology-Dependent Recombination Repair, Prolongation of G2/M Phase, and Protection from Apoptosis , 2002, Molecular and Cellular Biology.

[17]  T. Skorski,et al.  Oncogenic tyrosine kinases and the dna-damage response , 2002, Nature Reviews Cancer.

[18]  R. Herrmann,et al.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.

[19]  H. Mizoguchi,et al.  Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors. , 2002, Cancer letters.

[20]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[21]  C. Peschel,et al.  BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study , 2002, The Lancet.

[22]  M. Shibuya,et al.  TFIIH functions are altered by the P210BCR-ABL oncoprotein produced on the Philadelphia chromosome. , 2001, Mutation research.

[23]  T. Honjo,et al.  The IL-7 receptor controls the accessibility of the TCRgamma locus by Stat5 and histone acetylation. , 2001, Immunity.

[24]  R. Fishel,et al.  BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. , 2001, Molecular cell.

[25]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[26]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[27]  J. Melo,et al.  Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.

[28]  J. Zalcberg,et al.  Regulation of MDR1 gene expression: emerging concepts. , 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[29]  M. Varella‐Garcia,et al.  Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. , 2000, Blood.

[30]  A. Tomkinson,et al.  DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis , 1999, Oncogene.

[31]  H. Kantarjian,et al.  Multidrug resistance protein expression in chronic myeloid leukemia , 1999, Cancer.

[32]  B. Calabretta,et al.  Signal Transducer and Activator of  Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for Leukemogenesis , 1999, The Journal of Experimental Medicine.

[33]  H. Mizoguchi,et al.  Down-regulation of telomerase activity is an early event of cellular differentiation without apparent telomeric DNA change. , 1998, Leukemia research.

[34]  S. Vispé,et al.  Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. , 1998, Nucleic acids research.

[35]  A. Baryshnikov,et al.  Prognostic value of P-glycoprotein and leukocyte differentiation antigens in chronic myeloid leukemia. , 1998, Leukemia & lymphoma.

[36]  J. Melo,et al.  The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. , 1997, Blood.

[37]  M. Greaves,et al.  ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. , 1996, Oncogene.

[38]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[39]  W. El-Deiry,et al.  BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. , 1995, Blood.

[40]  K. Oshimi,et al.  Telomeric DNA in normal and leukemic blood cells. , 1995, The Journal of clinical investigation.

[41]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[42]  N. Heisterkamp,et al.  Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. , 1994, Blood.

[43]  I. Roninson,et al.  Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. , 1993, Journal of the National Cancer Institute.

[44]  T. Tsuruo,et al.  Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. , 1986, Japanese journal of cancer research : Gann.

[45]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[46]  C. Lozzio,et al.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. , 1975, Blood.

[47]  K. Danø.  Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. , 1973, Biochimica et biophysica acta.

[48]  E. Wagner,et al.  Stat5 tetramer formation is associated with leukemogenesis. , 2005, Cancer cell.